Business
Transfer of urine samples to Thermo Fisher
Transfer of urine samples to Thermo Fisher.
About this update from Verici Dx Plc
Verici Dx plc (" Verici Dx " or the " Company ") Transfer of urine samples to Thermo Fisher Scientific Following completion of the transfer, full payment has been received Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has completed successful transfer of a portion of the Company's urine samples as announced as part of the global commercialisation and licensing agreement announced in November 2023 1 . A s previously stated, it demonstrates the additional value in the Company's data and sample assets for research. Sara Barrington, CEO, said: "We are delighted to announce the successful completion of this transfer, within the agreed timeline. This achievement not only highlights our commitment to delivering on our agreements, but also underscores the substantial value inherent in the Company's data and sample assets for research purposes. " Enquiries: Verici Dx www.v ericidx .com Sara Barrington, CEO [email protected] Julian Baines, Chairman Singer Capital Markets (Nominated Adviser & Broker) Tel: +44 20 7496 3000 Aubrey Powell / Sam Butcher Notes 1. Please refer to RNS number 4652T for further information. A copy of this announcement can also be found on the company website https://verici-dx-plc.flint-platform.com/regulatory-news/44270 About Verici Dx plc www.vericidx.com Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners. The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.